These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11028131)

  • 1. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
    Brown MG; Murray TJ; Sketris IS; Fisk JD; LeBlanc JC; Schwartz CE; Skedgel C
    Int J Technol Assess Health Care; 2000; 16(3):751-67. PubMed ID: 11028131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
    Parkin D; Jacoby A; McNamee P; Miller P; Thomas S; Bates D
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):144-9. PubMed ID: 10644777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
    Touchette DR; Durgin TL; Wanke LA; Goodkin DE
    Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
    Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
    Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.
    Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
    Int J Technol Assess Health Care; 2000; 16(3):768-80. PubMed ID: 11028132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
    Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
    Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
    Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
    J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.